Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome

Completed · Phase 1

Conditions studied: Leukemia, Myelodysplastic Syndromes

In brief

RATIONALE: A vaccine made from a person's myelodysplasia cells may make the body build an immune response to kill cancer cells. Combining vaccine therapy with sargramostim may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus sargramostim in treating patients who have myelodysplastic syndrome.

Key facts

Study ID

NCT00003959

Run by

Memorial Sloan Kettering Cancer Center

People needed

1

Starts

1999-06-01

Last updated by the study team

2013-01-16

Who can join

Age: 17 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.